Daehwa Pharmaceutical accelerates to launch the world’s first oral paclitaxel antibody
Daehwa Pharmaceutical announced it applied manufacturing, sales and product approvals of ‘DHP107,’ the world’s first oral paclitaxel-type modified drug, to the Ministry of Food and Drug Safety on the 12th.
DHP107 proved equivalence(non-inferior model) in safety and evaluation variables of effect...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
